Phase II Study of Preoperative Intra-Arterial Epirubicin, Etoposide, and Oxaliplatin Combined with Oral S-1 Chemotherapy for the Treatment of Borrmann Type 4 Gastric Cancer

Xiao-song Xiang; Yu Su; Guo-li Li; Long Ma; Chang-sheng Zhou; Ru-feng Ma

추천

검색

자료유형: 학술저널

저자정보: Xiao-song Xiang (Nanjing University) Yu Su (Nanjing University) Guo-li Li (Nanjing University) Long Ma (Nanjing University) Chang-sheng Zhou (Nanjing University) Ru-feng Ma (Nanjing University)

저널정보: 대한위암학회 Journal of Gastric Cancer Journal of Gastric Cancer 제20권 제4호

발행연도: 2020.1

수록면: 395 - 407 (13page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: A phase II study was conducted to evaluate the safety and efficacy of preoperative, intra-arterial perfusion of epirubicin, etoposide, and oxaliplatin combined with oral chemotherapy S-1 (SEEOX) for the treatment of type 4 gastric cancer. Materials and Methods: A single-center, single-arm phase II trial was conducted on 36 patients with histologically proven type 4 gastric cancer without distant peritoneal or organ metastasis. Patients received 3, 21-day courses of SEEOX preoperative chemotherapy. The primary endpoint was overall survival (OS) and the secondary outcomes assessed were chemotherapeutic response, radical resection rate, pathological regression, toxicities, postoperative morbidity, and mortality. Results: All patients were at an advanced stage of cancer (stage III or IV) and completed the entire course of treatment. Based on changes in tumor volume and peritoneal metastasis, the objective response rate was 55.6% (20/36; 95% confidence interval [CI], 38.5%?72.6%) and the disease control rate was 69.4% (25/36; 95% CI, 53.6%?85.3%). The radical resection rate was 75% (27/36; 95% CI, 60.1%?89.9%) and the proportion of R0 resections was 66.7% (21/36; 95% CI, 50.5%?82.8%). The pathological response rate was 33.3%, of which 13.9% showed complete pathological regression. The median survival was 27.1 months (95% CI, 22.24?31.97 months), and the 2-year OS was 48.5% (95% CI, 30.86%?66.1%). Conclusions: Preoperative SEEOX is a safe and effective treatment for type 4 gastric cancer. Based on these preliminary data, a phase III study will be conducted to confirm the superiority of this regimen over standard treatment.

#Gastric cancer #Neoadjuvant chemotherapy #Linitis plastica

참고문헌 (28)

참고문헌 신청

Torre LA / 2015 / Global cancer statistics, 2012 / CA Cancer J Clin 65:87~108

An JY / 2008 / Borrmann type IV : an independent prognostic factor for survival in gastric cancer / J Gastrointest Surg 12:1364~1369

Jae Bong Ahn / 2011 / An Insufficient Preoperative Diagnosis of Borrmann Type 4 Gastric Cancer in Spite of EMR / Journal of Gastric Cancer 11(1):59~63

Miki Y / 2015 / Staging laparoscopy for patients with cM0, type 4, and large type 3 gastric cancer / World J Surg 39:2742~2747

Edge SB / 2010 / AJCC Cancer Staging Manual / Springer

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!